Accepting PhD Students

PhD projects

PhD and MPhil projects are available. Current research interests include: -Neuropathophysiology of Duchenne muscular dystrophy -RNA processing of the dystrophin gene -Therapeutic targeting of dystrophin in the brain -Role of the DMD gene in cancer -RNA processing in neurodegeneration -RNA-based gene therapy/therapeutics Please get in touch by e-mail or telephone.

Willing to speak to media

20072021

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Karen studied biochemistry at the University of Leeds spending one year as a sandwich student at GlaxoSmithKline (GSK), Essex.  At GSK Karen experienced the drug discovery process through performing large-scale purifications of protein drug targets.  Developing a strong interest in neurodegeneration Karen joined the lab of Dr Jean-Marc Gallo at the Institute of Psychiatry, King’s College London.  Her PhD “tau RNA processing in neurodegeneration: trans-acting factors regulating alternative splicing and mRNA localisation” was awarded in 2009.  As a post-doc in Dr Gallo’s lab Karen established proof-of-concept for RNA reprogramming strategies including RNA trans-splicing therapies for spinocerebellar ataxia type 1 and the tauopathies.  In 2010 Karen successfully translated her RNA expertise to the neuromuscular field and moved to the Dubowitz Neuromuscular Centre, Institute of Child Health, University College London (UCL).  Working with Professor Francesco Muntoni, Karen played a key role in developing antisense oligonucleotide-mediated exon skipping as a therapeutic strategy for Duchenne muscular dystrophy (DMD).  Her pre-clinical and clinical work in this area culminated in the first FDA-approved drug for DMD.  In 2015 Karen attained a lectureship at the University of Northampton where she founded and leads the Molecular Biosciences Research Group.  Her laboratory investigates the molecular mechanisms of neurological disorders with a focus on the neuropathophysiology of DMD.  Karen also consults for international pharmaceutical and biotechnology companies on methodology for clinical trial biochemical outcome measures and the development of exon skipping therapies.

Research Interests

Karen’s research is focused on RNA processing and the molecular mechanisms of neurodegeneration and neuromuscular disorders.  Current research projects and interests include:

-Neuropathophysiology of Duchenne muscular dystrophy

-The role of the DMD gene in cancer

-RNA processing of the dystrophin gene

-Therapeutic targeting of dystrophin in the brain

-RNA processing in neurodegeneration

-RNA-based gene therapy/therapeutics

Supervision

Amanda Ash; Sports, Exercise and Life Science

Cell migration in the neuropathophysiology of Duchenne muscular dystrophy

Michael Naidoo; Sports, Exercise and Life Science

The role of dystrophin in neurological malignancies.

Leanne Jones; Life Sciences

The role of dystrophin in head and neck cancers

Bill Robertson-Smith, Health and Society

Recurrence of synovial sarcoma: risk factors for relapse in a U.K. population.

Nermin Albalbeisi; Sports, Exercise and Life Science

Potential role of PAD2 in Ovarian Cancer.

 

Teaching Interests

Undergraduate teaching:

Karen teaches across the BSc (Hons) in Human Bioscience, Biomedical Science Biology programmes:

Module Leader:

  • SLS1017: Science Communication
  • SLS3010: Molecular and Cellular Neuroscience
  • SLS4005: Human Bioscience Dissertation

Teaching on other modules:

  • SLS2001: Genes and Genomics
  • SLS2010: Health and Disease 2
  • SLS2013: Bioscience Research Methods
  • SLS3002: Integrated Medical Genetics

Postgraduate teaching (taught programmes) 

  • MSc in Molecular Bioscience 

Expertise related to UN Sustainable Devlopment Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being

Education/Academic qualification

Master, University of Northampton

20162017

PhD, King's College London

20052009

Bachelor, University of Leeds

20012005

GlaxoSmithKline

20032004

Keywords

  • RM Therapeutics. Pharmacology
  • RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
  • RC0254 Neoplasms. Tumors. Oncology (including Cancer)
  • QP Physiology
  • QM Human anatomy
  • QH301 Biology
  • QH426 Genetics

Fingerprint

Dive into the research topics where Karen Anthony is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles